{"transactions":[{"id":1547118,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547117,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":84599,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547116,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1368338,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547115,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4738453,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547114,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1368339,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1665594,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":469615,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, L.P. (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":469615},"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665593,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":469615,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP IV\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":469615},"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665592,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":821827,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, L.P. (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":821827},"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665591,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":821827,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP IV\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":821827},"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665590,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":222222,"price":18,"value":3999996.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Reflects shares purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, L.P. (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1513664,"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665589,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":222222,"price":18,"value":3999996.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Reflects shares purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP IV\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1513664,"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665588,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":true,"shares":469615,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, L.P. (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1291442,"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665587,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":true,"shares":469615,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP IV\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1291442,"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665586,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":true,"shares":821827,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, L.P. (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":821827,"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665585,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":true,"shares":821827,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP IV\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":821827,"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1901251,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":490511,"price":2.82,"value":1383241.02,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.80 to a high of $2.89 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1368338,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1901250,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":490512,"price":2.82,"value":1383243.84,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.80 to a high of $2.89 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1368339,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1901249,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-04","kind":"purchase","planned":false,"acquired":true,"shares":83459,"price":2.75,"value":229512.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.75 to a high of $2.86 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":877827,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1901248,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-04","kind":"purchase","planned":false,"acquired":true,"shares":312991,"price":2.75,"value":860725.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.75 to a high of $2.86 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4738453,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1901247,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T21:22:18.000Z","date":"2023-05-04","kind":"purchase","planned":false,"acquired":true,"shares":83459,"price":2.75,"value":229512.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.75 to a high of $2.86 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":877827,"source":{"system":"sec-edgar","filing":"0000947871-23-000541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000541/ownership.xml","form_type":"4"}},{"id":1908956,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":58826,"price":2.67,"value":157065.42,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.57 to a high of $2.82 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":794368,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908955,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":220610,"price":2.67,"value":589028.7,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.57 to a high of $2.82 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4425462,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908954,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":58826,"price":2.67,"value":157065.42,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.57 to a high of $2.82 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":794368,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908953,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-01","kind":"purchase","planned":false,"acquired":true,"shares":124545,"price":2.62,"value":326307.9,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.59 to a high of $2.64 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":735542,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908952,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-01","kind":"purchase","planned":false,"acquired":true,"shares":467068,"price":2.62,"value":1223718.16,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.59 to a high of $2.64 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4204852,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908951,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-05-01","kind":"purchase","planned":false,"acquired":true,"shares":124544,"price":2.62,"value":326305.28,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.59 to a high of $2.64 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":735542,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908950,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-04-28","kind":"purchase","planned":false,"acquired":true,"shares":60997,"price":2.55,"value":155542.35,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":610997,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908949,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-04-28","kind":"purchase","planned":false,"acquired":true,"shares":228754,"price":2.55,"value":583322.7,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3737784,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1908948,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T01:34:38.000Z","date":"2023-04-28","kind":"purchase","planned":false,"acquired":true,"shares":60998,"price":2.55,"value":155544.9,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":610998,"source":{"system":"sec-edgar","filing":"0000947871-23-000515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000515/ownership.xml","form_type":"4"}},{"id":1996587,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-23T19:16:09.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":550000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was previously reported on the Form 3 jointly filed by OrbiMed Capital GP VIII LLC (\"GP VIII\"), OrbiMed Asia GP IV, L.P. (\"Asia GP\"), and OrbiMed Advisors IV Limited (\"Advisors IV\") on February 23, 2023 and is reported on this Form 4 as a transaction by OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the Issuer's common stock were acquired from the Issuer in exchange for Series A preferred shares of Kinnjiu Biopharma Inc. pursuant to a transaction approved by an independent committee of the Issuer's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). Asia GP is the general partner of OAP IV and Advisors IV is the general partner of Asia GP. OrbiMed Advisors is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":550000,"source":{"system":"sec-edgar","filing":"0000947871-23-000220","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000220/ownership.xml","form_type":"4"}},{"id":1996586,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-23T19:16:09.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":550000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was previously reported on the Form 3 jointly filed by OrbiMed Capital GP VIII LLC (\"GP VIII\"), OrbiMed Asia GP IV, L.P. (\"Asia GP\"), and OrbiMed Advisors IV Limited (\"Advisors IV\") on February 23, 2023 and is reported on this Form 4 as a transaction by OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the Issuer's common stock were acquired from the Issuer in exchange for Series A preferred shares of Kinnjiu Biopharma Inc. pursuant to a transaction approved by an independent committee of the Issuer's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). GP VIII is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":550000,"source":{"system":"sec-edgar","filing":"0000947871-23-000220","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000220/ownership.xml","form_type":"4"}}]}